Clinical Trial

A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 28, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-11; most recent amendment 2025-10-27.
Trial Details
NCT Number NCT07064486
Lead Sponsor BrightGene Bio-Medical Technology Co., Ltd.
Conditions Type 2 Diabetes (T2DM)
Enrollment 477 participants
Start Date 2025-07-04
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-28